Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5458250 | 0.77 | RAB9A (0.57) | KDM4ERAB9ANPC1CDC7DBF4 | |
| Hydrochloric Acid SCHEMBL11113246 | 0.75 | KDM4E (0.49) | KDM4ERAB9ANPC1CDC7DBF4 | |
| SCHEMBL5453146 | 0.73 | ADORA3 (0.44) | KDM4ERAB9ANPC1HTTADORA3 | |
| SCHEMBL22983506 | 0.69 | NPC1 (0.52) | KDM4ERAB9ANPC1HTTSMN1; SMN2 | |
| SCHEMBL5458126 | 0.69 | MAPK10 (0.52) | KDM4ECDC7ADORA3ADORA2AADORA1 | |
| SCHEMBL6569263 | 0.68 | CDK4 (0.39) | KDM4EADORA3ADORA2AADORA1L3MBTL1 | |
| SCHEMBL25974797 | 0.66 | RAB9A (0.57) | KDM4ERAB9ANPC1CDC7DBF4 | |
| SCHEMBL5569010 | 0.65 | PDE4D (0.57) | KDM4ERAB9ANPC1SMN1; SMN2PDE4D | |
| SCHEMBL31560197 | 0.64 | CCNT1 (0.56) | KDM4ERAB9ANPC1CDC7DBF4 | |
| SCHEMBL13309931 | 0.62 | ADORA1 (0.63) | KDM4ERAB9ANPC1CDC7DBF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232623-A1 | Pyrazolopyrimidine and Pyrazolotriazine Derivatives and Pharmaceutical Compositions Containing Them | GUDMUNDSSON KRISTJAN | 2007-10-04 | — | — | US | disclosed |
| US-7247626-B2 | Pyrazolopyrimidine derivatives and pharmaceutical compositions containing them | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1485385-B1 | PYRAZOLOPYRIMIDINE AND PYRAZOLOTRIAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050124616-A1 | Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them | SMITHKLINE BEECHAM CORPORATION | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124616-A1 | Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them | CYP3A5, CYP3A4, CYP3A7 | KDM4E 1997/4885RAB9A 3001/4885NPC1 801/4885 |
| US-20070232623-A1 | Pyrazolopyrimidine and Pyrazolotriazine Derivatives and Pharmaceutical Compositions Containing Them | CYP3A5, CYP3A4, CYP3A7 | KDM4E 1997/4885RAB9A 3001/4885NPC1 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.